气喘市场：KOL洞察

本报告深入探讨了不断发展的气喘治疗领域，提供了顶级 KOL 对气喘治疗的最新见解，包括 GSK 的depemoximab、Tezspire 的市场动态和 dexpramipexole 等新疗法，强调了最近临床试验的主要发现以及新疗法对当前实践的影响。

报告内容

• 未来 3 至 5年影响气喘治疗的重大变化
• 进行中的临床试验将如何影响Amgen/AstraZeneca抗 TSLP 单株抗体 Tezspire 的未来使用？
• 抗 IL5 疗法和 Dupixent 是治疗严重气喘的成熟生物製剂，但 GSK 的长效抗 IL5 药物 depemoximab 能带来多大的颠覆性？
• 专家认为GSK的Trelegy Ellipta、Novartis的Enerzair Breezhaler 和 Chiesi 的Trimbow 这三重组合方案在治疗气喘方面有何作用，AstraZeneca的Breztri/Trixeo Aerosphere 是否也有潜在作用？
• KOL 如何评估Sanofi口服 BTK 抑制剂 rilzabrutinib 影响气喘治疗实务的可能性？
• 专家如何评估 Knopp Biosciences 的口服多巴胺受体促效剂 dexpramipexole 在 III 期试验 EXHALE-2、-3 和 -4 中治疗气喘患者的成功几率？

主要品牌

Explore the latest insights from top KOLs on asthma therapies, including GSK's depemokimab, Tezspire's market dynamics, and novel treatments like dexpramipexole. This report delves into the evolving landscape of asthma treatment, highlighting key findings from recent clinical trials and the impact of emerging therapies on current practice.

Key Questions Answered:

• What will be the major changes to impact the treatment of asthma over the next three to five years?
• How could ongoing clinical trials impact the future use of Amgen/AstraZeneca's anti-TSLP monoclonal antibody Tezspire?
• The anti-IL5 therapies and Dupixent are well-established biologics for severe asthma, but just how disruptive could GSK's long-acting anti-IL5 agent depemokimab be?
• How do experts view the role of fixed-dose triple-combination therapies (GSK's Trelegy Ellipta, Novartis' Enerzair Breezhaler and Chiesi's Trimbow) in asthma, and could AstraZeneca's Breztri/Trixeo Aerosphere find a role?
• How do the KOLs assess the prospects for Sanofi's oral BTK inhibitor rilzabrutinib to impact asthma treatment practice?
• With the Phase III EXHALE-2, -3 and -4 trials evaluating Knopp Biosciences' dexpramipexole in the treatment of patients with asthma, how do experts weigh up this oral dopamine receptor agonist's prospects for success?

Key Brands:

Partial List of Participating Experts:

• Professor of Pediatrics, Allergy/Immunology/Pulmonary Medicine, Scientific Director of the Center for Clinical and Translational Research, Vanderbilt University Medical Center, USA
• Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, USA
• Clinical Professor of Medicine, University of Medicine and Dentistry of New Jersey - Rutgers, Director of Clinical Research at Pulmonary and Allergy Associates, USA
• Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, Senior Research Investigator at Imperial College, UK
• Head of Pulmonology, Consultant and Professor of Respiratory Medicine at Arnaud de Villeneuve Hospital/University of Montpellier, France
• Head of Department of Allergy, La Paz University Hospital, IdiPAZ, CIBER of Respiratory Diseases (CIBERES), Universidad Autenoma de Madrid, Spain

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.